stockportfolio.pro
United Therapeutics Corporation P/E Ratio 2008–2025
United Therapeutics Corporation (UTHR) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -11.9%/yr over 17 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 17.49 | +22.1% |
| FY 2024 | 14.32 | +29.0% |
| FY 2023 | 11.10 | -40.1% |
| FY 2022 | 18.54 | -13.7% |
| FY 2021 | 21.48 | +63.3% |
| FY 2020 | 13.15 | — |
| FY 2019 | — | — |
| FY 2018 | 8.13 | -48.8% |
| FY 2017 | 15.89 | +69.0% |
| FY 2016 | 9.41 | -23.6% |
| FY 2015 | 12.31 | -40.3% |
| FY 2014 | 20.62 | -40.2% |
| FY 2013 | 34.48 | +268.5% |
| FY 2012 | 9.36 | -27.3% |
| FY 2011 | 12.87 | -63.8% |
| FY 2010 | 35.52 | -76.4% |
| FY 2009 | 150.43 | — |
| FY 2008 | — | — |
Source: United Therapeutics Corporation SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for United Therapeutics Corporation
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeUnited Therapeutics Corporation — frequently asked questions
What is United Therapeutics Corporation's price-to-earnings ratio?
United Therapeutics Corporation (UTHR) reported price-to-earnings ratio of 17.49 for fiscal year 2025, per its SEC filings.
How has United Therapeutics Corporation's price-to-earnings ratio changed over time?
Between fiscal 2008 and 2025, UTHR's price-to-earnings ratio declined at roughly 11.9% per year (compound annual rate), from 150.43 to 17.49.
Where does this data come from?
Figures are computed from United Therapeutics Corporation's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.